From: Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
Characteristic | All patients |
---|---|
 | N(%) |
No. of patients | 50 |
Median age | 48 (26-72 years) |
< 40 years | 12 (24%) |
≥40 years | 38 (76%) |
Ethnicity | Â |
Caucasian | 34 (68%) |
African American | 15 (30%) |
Other | 1 (2%) |
Stage | N = 34 |
I | 4 (12%) |
II | 17 (50%) |
III | 10 (29%) |
IV | 3 (9%) |
IHC subtype | N = 43 |
HR+/HER2- | 12 (28%) |
HR-/HER2- (TN) | 19 (44%) |
HER2+ | 12 (28%) |
Systemic therapy for primary BC | Â |
Chemotherapy | 44/48 (92%) |
Endocrine therapy (for HR+/HER2-) | 6/11 (55%) |
Trastuzumab (for HER2+) | 2/12 (17%) |
Systemic therapy for metastatic BC | Â |
Chemotherapy | 28/38 (74%) |
Endocrine therapy (for HR+/HER2-) | 7/10 (70%) |
Her2-directed therapy (for HER2+) | 6/9 (67%) |
BCBM therapy | N = 47 |
Cranial XRT | 25 (53%) |
Radiosurgery | 4 (9%) |